Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 1

DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 2

DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 3

Trial Locations (18)

23294

National Clinical Research - Richmond, Inc., Richmond

23502

National Clinical Research - Norfolk, Inc, Norfolk

32806

Compass Research, Orlando

33136

Diabetes Research Institute, Miami

45219

The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati

45439

Providence Health Partners - Center for Clinical Reseach, Dayton

59701

Big Sky Clinical Research, Butte

70112

Tulane University Medical Center, New Orleans

70808

Pennington Biomedical Research Center, Baton Rouge

75230

Dallas Diabetes and Endocrine Center, Dallas

77055

West Houston Clinical Research Services, Houston

78205

Paragon Research Center, San Antonio

84107

Wasatch Clinical Research, Salt Lake City

89052

Desert Endocrinology Clinical Research Center-Henderson, Henderson

89101

Alliance Against Diabetes/AAD Clinical Research, Las Vegas

92844

SC Clinical Research, Garden Grove

98502

Capital Clinical Research Center, Olympia

03801

Active Practices and Research, Newington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mesoblast, Ltd.

INDUSTRY

NCT01576328 - Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes | Biotech Hunter | Biotech Hunter